Valuation: HitGen Inc.

Market Cap 11.07B 1.64B 1.44B 1.34B 1.23B 2.3B 157B 2.34B 15.86B 6.2B 77.41B 6.14B 6.01B 268B P/E 2026 *
81.3x
P/E 2027 * 63.5x
Enterprise Value 11.07B 1.64B 1.44B 1.34B 1.23B 2.3B 157B 2.34B 15.86B 6.2B 77.41B 6.14B 6.01B 268B EV / Sales 2026 *
17.4x
EV / Sales 2027 * 14.2x
Free-Float
50.43%
Yield 2026 *
0.31%
Yield 2027 * 0.54%
1 day-2.37%
1 week-6.97%
Current month-13.95%
1 month-12.59%
3 months+5.26%
6 months-17.77%
Current year+17.83%
1 week 25.85
Extreme 25.85
30.45
1 month 25.85
Extreme 25.85
38.67
Current year 22.42
Extreme 22.42
42.98
1 year 21.46
Extreme 21.46
42.98
3 years 8.35
Extreme 8.35
42.98
5 years 8.35
Extreme 8.35
42.98
10 years 8.35
Extreme 8.35
61.99
Manager TitleAgeSince
Chief Executive Officer 63 2012-05-31
Director of Finance/CFO 56 2023-04-26
Investor Relations Contact 38 2019-06-30
Director TitleAgeSince
Chairman 63 2012-05-31
Director/Board Member 63 -
Director/Board Member 65 2019-03-23
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%-6.97%+20.92%+79.77% 1.64B
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.17%+0.87%+38.26%+158.44% 24.17B
Weighted average by Cap. -0.88%+2.06%+39.57%+133.13%

Financials

2026 *2027 *
Net sales 638M 94.21M 82.75M 76.95M 70.62M 133M 9.07B 135M 914M 357M 4.46B 354M 346M 15.42B 781M 115M 101M 94.22M 86.46M 162M 11.11B 165M 1.12B 437M 5.46B 433M 424M 18.88B
Net income 137M 20.23M 17.76M 16.52M 15.16M 28.48M 1.95B 28.92M 196M 76.64M 958M 75.93M 74.29M 3.31B 174M 25.72M 22.59M 21M 19.27M 36.21M 2.48B 36.77M 249M 97.45M 1.22B 96.54M 94.46M 4.21B
Net Debt - -
Logo HitGen Inc.
HitGen Inc is a China-based company primarily engaged in the research, development and optimization of small molecule and nucleic acid-based new drug candidates using deoxyribonucleic acid (DNA) encoded chemical library (DEL) technology. Through the drug discovery and optimization platform, the Company provides clients with services such as screening and optimization of designated biological targets, customized DEL design and synthesis, synthesis and modification of certain designated compounds or nucleic acids and related biological evaluation. The Company is also engaged in the transfer of rights and interests in new drug research projects, capital operations and marketing activities. The Company primarily operates its businesses in the domestic market and overseas markets, including the United States, France, the United Kingdom and Japan.
Employees
546
Date Price Change Volume
26-07-24 CN¥27.63 -2.37% 19,050,441
26-07-23 CN¥28.30 +0.35% 18,491,070
26-07-22 CN¥28.20 -2.49% 18,453,424
26-07-21 CN¥28.92 +1.72% 23,090,104
26-07-20 CN¥28.43 -4.28% 23,435,684
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.63CNY
Average target price
31.60CNY
Spread / Average Target
+14.37%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688222 Stock